XENETIC BIOSCIENCES INC (XBIO) Stock Price, Forecast & Analysis
NASDAQ:XBIO • US9840156023
XBIO Key Statistics, Chart & Performance
The current stock price of XBIO is 2.53 USD. In the past month the price increased by 8.58%. In the past year, price decreased by -35.46%.
XBIO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to XBIO. When comparing the yearly performance of all stocks, XBIO is a bad performer in the overall market: 83.82% of all stocks are doing better.
XBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XBIO. The financial health of XBIO is average, but there are quite some concerns on its profitability.
XBIO Financial Highlights
Over the last trailing twelve months XBIO reported a non-GAAP Earnings per Share(EPS) of -2.57. The EPS increased by 6.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.28% | ||
| ROE | -79.78% | ||
| Debt/Equity | 0 |
XBIO Forecast & Estimates
For the next year, analysts expect an EPS growth of 19.04% and a revenue growth 13.64% for XBIO
XBIO Ownership
XBIO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 410.174B | ||
| AMGN | AMGEN INC | 17.23 | 209.016B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 184.799B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 126.056B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 82.638B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.982B | ||
| INSM | INSMED INC | N/A | 31.848B | ||
| NTRA | NATERA INC | N/A | 28.947B | ||
| BIIB | BIOGEN INC | 12.61 | 28.152B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.698B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XBIO
Company Profile
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2016-11-07. The firm is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The firm's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. The company is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.
Company Info
XENETIC BIOSCIENCES INC
945 Concord St.
Framingham MASSACHUSETTS 01701 US
CEO: Jeffrey F. Eisenberg
Employees: 2
Phone: 17817787720
XENETIC BIOSCIENCES INC / XBIO FAQ
Can you describe the business of XENETIC BIOSCIENCES INC?
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2016-11-07. The firm is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The firm's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. The company is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.
What is the current price of XBIO stock?
The current stock price of XBIO is 2.53 USD. The price increased by 4.55% in the last trading session.
Does XENETIC BIOSCIENCES INC pay dividends?
XBIO does not pay a dividend.
What is the ChartMill rating of XENETIC BIOSCIENCES INC stock?
XBIO has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of XENETIC BIOSCIENCES INC (XBIO) based on its PE ratio?
XENETIC BIOSCIENCES INC (XBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.57).
Would investing in XENETIC BIOSCIENCES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on XBIO.
Is XENETIC BIOSCIENCES INC (XBIO) expected to grow?
The Revenue of XENETIC BIOSCIENCES INC (XBIO) is expected to grow by 13.64% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.